Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China; Longhua Hospital, Institute of Spine, Shanghai University of Traditional Chinese Medicine, Key Laboratory, Ministry of Education of China, Shanghai 200032, China.
Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China.
Biomed Pharmacother. 2022 Jun;150:112975. doi: 10.1016/j.biopha.2022.112975. Epub 2022 Apr 19.
Postmenopausal osteoporosis (PMOP) is a common disease that has decreased bone strength as its main symptom after menopause. Effective treatment for PMOP remains lacking, but traditional Chinese medicine has some advantages in delaying bone loss. Jiangu granule is a traditional Chinese medicine prescription commonly used to treat PMOP. Previous studies have demonstrated its efficacy, but the mechanism of action remains uncharacterized.
This study aims to observe and discuss the mechanism of Jiangu granule to ameliorate bone loss in OVX rats by regulating the gut microbiota (GM)-short-chain fatty acids (SCFAs)- Treg/Th17 axis.
Female SD rats were divided into the sham operation (S), Jiangu granule (J), and model group (M). Bilateral ovaries were surgically removed from the rats in the J and M groups. After 6 and 12 weeks, rats were sacrificed, and femur, tibia, vertebrae, serum, spleen, colon, and feces samples were collected. We detected the strength of bones, gut microbiota structure, and SCFAs in feces, the Treg and Th17 cell levels in the spleen, and cytokine levels in the serum.
Jiangu granule restored the abundance of gut microbiota, increased the content of SCFAs, reduced the permeability of colon epithelium, increased the proportion of Treg cells in the spleen, changed the osteoimmunomodulation-related cytokines, effectively prevented bone loss, and enhanced bone strength.
Jiangu granule can effectively improve bone loss in OVX rats, possibly by regulating the "GM-SCFAs-Treg/Th17″ axis.
绝经后骨质疏松症(PMOP)是一种常见疾病,其主要症状为绝经后骨强度下降。PMOP 的有效治疗方法仍然缺乏,但中医药在延缓骨丢失方面具有一定优势。健骨颗粒是一种常用于治疗 PMOP 的中药方剂。先前的研究已经证明了它的疗效,但作用机制尚不清楚。
本研究旨在通过调节肠道微生物群(GM)-短链脂肪酸(SCFAs)-Treg/Th17 轴观察和讨论健骨颗粒改善去卵巢大鼠骨丢失的机制。
将雌性 SD 大鼠分为假手术(S)、健骨颗粒(J)和模型组(M)三组。J 和 M 组大鼠行双侧卵巢切除术。6 和 12 周后,处死大鼠,采集股骨、胫骨、椎体、血清、脾脏、结肠和粪便样本。我们检测了骨强度、粪便中肠道微生物群结构和 SCFAs、脾脏中 Treg 和 Th17 细胞水平以及血清中细胞因子水平。
健骨颗粒恢复了肠道微生物群的丰度,增加了 SCFAs 的含量,降低了结肠上皮的通透性,增加了脾脏中 Treg 细胞的比例,改变了与骨免疫调节相关的细胞因子,有效预防了骨丢失,增强了骨强度。
健骨颗粒可有效改善去卵巢大鼠的骨丢失,可能通过调节“GM-SCFAs-Treg/Th17”轴。